Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
13 07 2022
13 07 2022
Historique:
received:
19
04
2022
accepted:
04
07
2022
entrez:
13
7
2022
pubmed:
14
7
2022
medline:
16
7
2022
Statut:
epublish
Résumé
Biomarker in metastatic castration resistant prostate cancer (mCRPC) treatment are rare. We aimed to compare the clinical value of circulating tumor cells (CTCs) and androgen receptor splice variant 7 (AR-V7) as biomarker in mCRPC patients undergoing androgen receptor-targeted agent (ARTA) treatment. Overall cohort (65 patients) was stratified regarding either CTC or AR-V7 status followed by further sub-stratification of the respective other marker. Subsequently, prostate specific antigen (PSA) response, progression free survival (PFS) and overall survival (OS)) of subgroups was compared. CTCs and AR-V7 were detected in 54 (83%) and 33 (61%) patients, respectively. All AR-V7 + were CTC +. We detected PSA response in all subgroups. For PFS and OS, biomarker stratification revealed differences between all subgroups. Interestingly, no significant differences of AR-V7 transcript copy numbers were detected between responding and non-responding patients. Additionally, multivariable analysis revealed no independent prognostic value of AR-V7 positivity. Both biomarkers show clinical value in prognosticating clinical outcome. Nonetheless, AR-V7 stratification underestimates the heterogenous subgroup of CTC - and CTC + patient, the latter requiring more intense clinical surveillance. Additionally, AR-V7 level does not correlate with clinical response. Thus, the value of AR-V7 as a clinical biomarker must be considered skeptically.
Identifiants
pubmed: 35831403
doi: 10.1038/s41598-022-16094-6
pii: 10.1038/s41598-022-16094-6
pmc: PMC9279395
doi:
Substances chimiques
Biomarkers, Tumor
0
Protein Isoforms
0
Receptors, Androgen
0
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
11846Informations de copyright
© 2022. The Author(s).
Références
Clin Cancer Res. 2008 Oct 1;14(19):6302-9
pubmed: 18829513
Clin Cancer Res. 2015 Jul 1;21(13):2883-5
pubmed: 26133774
Int J Cancer. 2021 Feb 1;148(3):528-545
pubmed: 32683679
J Clin Oncol. 2016 Apr 20;34(12):1402-18
pubmed: 26903579
Clin Cancer Res. 2019 Jul 1;25(13):3856-3864
pubmed: 30992298
Eur Urol. 2018 Jun;73(6):818-821
pubmed: 29398263
JCO Precis Oncol. 2020 Oct 28;4:
pubmed: 33154984
Eur Urol. 2020 Apr;77(4):508-547
pubmed: 32001144
BJU Int. 2018 Aug;122(2):219-226
pubmed: 29359890
Eur Urol. 2017 Nov;72(5):828-834
pubmed: 28818355
N Engl J Med. 2014 Sep 11;371(11):1028-38
pubmed: 25184630
J Clin Oncol. 2015 Apr 20;33(12):1348-55
pubmed: 25800753
JAMA Oncol. 2018 Sep 1;4(9):1179-1186
pubmed: 29955787
Eur Urol. 2019 Dec;76(6):843-851
pubmed: 31542304
J Oncol. 2010;2010:617421
pubmed: 20016752
J Clin Oncol. 2019 May 1;37(13):1120-1129
pubmed: 30865549
J Clin Oncol. 2018 Feb 20;36(6):572-580
pubmed: 29272162
JAMA Oncol. 2016 Nov 01;2(11):1441-1449
pubmed: 27262168
Science. 2015 Sep 18;349(6254):1351-6
pubmed: 26383955
Eur Urol. 2016 Dec;70(6):985-992
pubmed: 27289566
Eur Urol Oncol. 2021 Aug;4(4):609-617
pubmed: 31676281
Ann Oncol. 2018 Jul 1;29(7):1554-1560
pubmed: 29741566
Eur J Cancer. 2019 Nov;121:48-54
pubmed: 31542641
Eur Urol. 2019 Nov;76(5):676-685
pubmed: 31036442
J Clin Oncol. 2017 Jul 1;35(19):2149-2156
pubmed: 28384066